SCHEMBL2848851

SCHEMBL2848851

C[C@H](Nc1nc2ccc(Oc3ccc([N+](=O)[O-])nc3)cc2s1)C1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
MAPT P10636 2/20 0.43
PKM P14618 1/20 0.43
CSF1R P07333 8/20 0.41
PDGFRB P09619 1/20 0.41
KIT P10721 1/20 0.41
PDGFRA P16234 1/20 0.41
FLT3 P36888 1/20 0.41
PTPN1 P18031 1/20 0.39
ITK Q08881 1/20 0.39
PI4KA P42356 2/20 0.39
PI4KB Q9UBF8 2/20 0.39
USP30 Q70CQ3 2/20 0.39
PIP5K1C O60331 1/20 0.39
PIK3CG P48736 1/20 0.39
SCD O00767 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2848854 1.00 RAB9A (0.43) RAB9ANPC1MAPTPKMCSF1R
SCHEMBL2851202 0.85 CSF1R (0.47) RAB9ANPC1MAPTPKMCSF1R
SCHEMBL2851204 0.85 CSF1R (0.47) RAB9ANPC1MAPTPKMCSF1R
SCHEMBL2842304 0.83 NPC1 (0.44) RAB9ANPC1MAPTPKMCSF1R
SCHEMBL2842309 0.83 NPC1 (0.44) RAB9ANPC1MAPTPKMCSF1R
SCHEMBL2850063 0.83 USP30 (0.48) RAB9ANPC1MAPTPKMCSF1R
SCHEMBL2850067 0.83 USP30 (0.48) RAB9ANPC1MAPTPKMCSF1R
SCHEMBL13322425 0.83 NPC1 (0.42) RAB9ANPC1MAPTPKMCSF1R
SCHEMBL2846759 0.82 CSF1R (0.55) RAB9ANPC1MAPTPKMCSF1R
SCHEMBL3637356 0.82 PTPN1 (0.38) RAB9ANPC1MAPTPKMCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2152700-B1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2013-12-11 EP disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
WO-2008144062-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE CSF1R, CSF3R, FLT3 RAB9A 1826/4885NPC1 2714/4885MAPT 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.